• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Eur Heart J Cardiovasc Imaging . Myocarditis following COVID-19 vaccination: magnetic resonance imaging study

tetano

Editor, Senior Moderator
Eur Heart J Cardiovasc Imaging


. 2021 Nov 5;jeab230.
doi: 10.1093/ehjci/jeab230. Online ahead of print.
Myocarditis following COVID-19 vaccination: magnetic resonance imaging study


Arthur Shiyovich[SUP] 1 [/SUP], Guy Witberg[SUP] 1 [/SUP], Yaron Aviv[SUP] 1 [/SUP], Alon Eisen[SUP] 1 [/SUP], Katia Orvin[SUP] 1 [/SUP], Maya Wiessman[SUP] 1 [/SUP], Tzlil Grinberg[SUP] 1 [/SUP], Avital Porter[SUP] 1 [/SUP], Ran Kornowski[SUP] 1 [/SUP], Ashraf Hamdan[SUP] 1 [/SUP]



Affiliations

Abstract

Aims: To describe the cardiac magnetic resonance (CMR) imaging findings of patients who developed myocarditis following messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccination.
Methods and results: The present study retrospectively evaluated patients with clinically adjudicated myocarditis within 42 days of the first Pfizer-BNT162b2 mRNA COVID-19 vaccination, between 20 December 2020 and 24 May 2021 who underwent CMR. A total of 15 out 54 patients (28%) with myocarditis underwent a CMR and were included, 100% males, median age of 32 years (interquartile range = 22.5-40). Most patients presented with chest pain (87%) and had an abnormal electrocardiogram (79%). The severity of the disease was mild in 67% and intermediate in 33%. All patients survived and one patient was readmitted during the study period. CMR was performed at a median of 65 days (range 3-130 days) following diagnosis. Median ejection fraction was 58% (range 51-74%) global- and regional wall motion abnormalities were present in one and three patients, respectively. Native T1 was available in 13/15 patients (2/3 in 3 T and 11/12 in the 1.5 T), with increased values among 6/13. Late gadolinium enhancement (LGE) was found among 13/15 patients with a median of 2% (range 0-15%) with inferolateral wall being the most common location (8/13). The patterns of the LGE were: mid-wall in six patients; epicardial in five patients; and mid-wall and epicardial in two patients.
Conclusions: Among patients who were diagnosed with post-vaccination clinical myocarditis, CMR imaging findings are mild and consistent with 'classical myocarditis'. The short-term clinical course and outcomes were favourable.

Keywords: COVID-19 vaccination; cardiac magnetic resonance; myocarditis.
 
Back
Top Bottom